BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28673319)

  • 1. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.
    Fujita M; Hasegawa A; Yamamori M; Okamura N
    J Exp Clin Cancer Res; 2017 Jul; 36(1):91. PubMed ID: 28673319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
    Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
    J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
    Chang HK; Kim DS; Chae JJ; Kim M; Myong JP; Lee KH; Lee MW; Park TC
    Biochem Biophys Res Commun; 2017 Jan; 482(4):843-848. PubMed ID: 27888104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma.
    Fujita M; Yagami T; Fujio M; Tohji C; Takase K; Yamamoto Y; Sawada K; Yamamori M; Okamura N
    Cancer Lett; 2011 Dec; 312(2):219-27. PubMed ID: 21903322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
    Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
    Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone-Induced Autophagic Cytotoxicity in Lung Adenocarcinoma Cell Lines.
    Tsujiya Y; Hasegawa A; Yamamori M; Okamura N
    Biol Pharm Bull; 2022; 45(3):276-283. PubMed ID: 35228393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
    Li M; Lee TW; Yim AP; Mok TS; Chen GG
    J Cell Physiol; 2006 Nov; 209(2):428-38. PubMed ID: 16883598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines.
    Yang YC; Tsao YP; Ho TC; Choung IP
    Int J Gynecol Cancer; 2007; 17(2):418-25. PubMed ID: 17316361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
    Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
    Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferator-activated receptor gamma ligand.
    Nonaka M; Tazuma S; Hyogo H; Kanno K; Chayama K
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e198-206. PubMed ID: 17868335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells.
    Zhu H; Pan X; Qi H; Wang X; Hou S; Han B; Liu Z; Xu L
    Oncol Rep; 2011 Jan; 25(1):81-90. PubMed ID: 21109961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
    Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
    Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational effect of PPARγ agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro.
    Liu Y; Zhu ZA; Zhang SN; Mou J; Liu L; Cui T; Pei DS
    Tumour Biol; 2013 Aug; 34(4):2409-18. PubMed ID: 23605322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
    Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
    Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.
    Vitale G; Zappavigna S; Marra M; Dicitore A; Meschini S; Condello M; Arancia G; Castiglioni S; Maroni P; Bendinelli P; Piccoletti R; van Koetsveld PM; Cavagnini F; Budillon A; Abbruzzese A; Hofland LJ; Caraglia M
    Biotechnol Adv; 2012; 30(1):169-84. PubMed ID: 21871555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth].
    Koirala K; Wan YL; Liu YC; Wang X; Cui W; Wang CL; Chen HN; Wang HY; Zhu J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 38(4):385-8. PubMed ID: 16892143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro.
    Liu JJ; Huang RW; Lin DJ; Peng J; Wu XY; Lin Q; Pan XL; Song YQ; Zhang MH; Hou M; Chen F
    Ann Oncol; 2005 Mar; 16(3):455-9. PubMed ID: 15642706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells.
    Cheng HC; Ho TC; Chen SL; Lai HY; Hong KF; Tsao YP
    Mol Vis; 2008 Jan; 14():95-104. PubMed ID: 18253093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1.
    Baek SJ; Kim JS; Nixon JB; DiAugustine RP; Eling TE
    J Biol Chem; 2004 Feb; 279(8):6883-92. PubMed ID: 14662774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
    Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.